Literature DB >> 7310230

Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation.

R L Edwards, F R Rickles, M Cronlund.   

Abstract

Activation of blood coagulation, as characterized by the occurrence of disseminated intravascular coagulation, increased levels of plasma FPA, and the local deposition of fibrin, is common in both experimental animals and patients with malignant tumors. Many mechanisms have been proposed for the mediation of this response to tumors, including tumor-associated proteases, platelet adherence to tumors, surface activation of blood coagulation by tumor cells, and activation of coagulation by tissue factor derived from either tumor tissue or reactive leukocytes. We have investigated the hypothesis that MTF generation may contribute to increased fibrin generation in cancer patients. Plasma FPA levels and in vitro unstimulated MTF generation were measured simultaneously in samples obtained from 35 patients with lung cancer. FPA levels were significantly elevated in these patients as compared to a group of 20 normal volunteers (p = 0.03). Although unstimulated MTF generation showed considerable variability in both the patients and the normal volunteers, a high degree of correlation was observed between simultaneous levels of FPA and MTF regardless of whether MTF was expressed per cell (r = 0.83), per monocyte (r = 0.95), or per volume of peripheral blood (r = 0.96). MTF generation was also significantly decreased in a group of patients receiving sodium warfarin (p less than 0.001). These results suggest a potential role for MTF generation in the activation of blood coagulation in neoplasia and also suggest the possibility that inhibition of MTF generation by warfarin may be partially responsible for the decreased FPA values previously reported in anticoagulated cancer patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7310230

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  35 in total

1.  Contribution of the monocyte to thrombotic potential.

Authors:  C R Spillert; E J Lazaro
Journal:  Agents Actions       Date:  1991-09

Review 2.  Procoagulant activity in gastroenterology.

Authors:  A Wakefield; Z Cohen; G Levy
Journal:  Gut       Date:  1990-02       Impact factor: 23.059

Review 3.  Activation of coagulation and angiogenesis in cancer: immunohistochemical localization in situ of clotting proteins and vascular endothelial growth factor in human cancer.

Authors:  M Shoji; W W Hancock; K Abe; C Micko; K A Casper; R M Baine; J N Wilcox; I Danave; D L Dillehay; E Matthews; J Contrino; J H Morrissey; S Gordon; T S Edgington; B Kudryk; D L Kreutzer; F R Rickles
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

Review 4.  Mononuclear phagocytes.

Authors:  M J Auger
Journal:  BMJ       Date:  1989-03-04

5.  A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy.

Authors:  C Rella; M Coviello; F Giotta; E Maiello; P Colavito; D Colangelo; M Quaranta; G Colucci; F Schittulli
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  Abnormal haemostasis in small cell lung cancer.

Authors:  R Milroy; J T Douglas; J Campbell; R Carter; G D Lowe; S W Banham
Journal:  Thorax       Date:  1988-12       Impact factor: 9.139

7.  Recalcification time in breast disease.

Authors:  C A Sofia; C R Spillert; J A Pastena; E J Lazaro
Journal:  J Natl Med Assoc       Date:  1988-11       Impact factor: 1.798

8.  Specificity of fibrinopeptide A (FpA) as a marker for gastrointestinal cancers before and after surgery.

Authors:  V Abbasciano; F Levato; G Zavagli
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

Review 9.  Role of plasma, platelets, and endothelial cells in tumor metastasis.

Authors:  G J Gasic
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

10.  Evaluation of procoagulant activity production and other coagulative functions in cancer patients receiving acid treated Salmonella minnesota R 595 (Re).

Authors:  G Miragliotta; G Di Vagno; R Nappi; D Fumarola; E Jirillo; C Galanos
Journal:  Eur J Epidemiol       Date:  1988-09       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.